Sirius Therapeutics Begins Phase 1 Clinical Trial of Next-Generation, Long-Acting Factor XI siRNA Anticoagulant for Treatment of Thromboembolic Disorders
Article contentSAN DIEGO & SHANGHAI — Sirius Therapeutics, announced it has dosed the first subject in a Phase 1, first-in-human…
